Loading...
Market
Will Pfizer's RSV vaccine ABRYSVO® capture more than 50% market share in the US for adults 18-59 by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from reputable health industry analytics firms or financial reports from Pfizer
Story
FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for At-Risk Adults 18-59, Addressing Lower Respiratory Tract Disease
Oct 23, 2024, 11:00 AM
The U.S. Food and Drug Administration (FDA) has approved Pfizer's RSV vaccine, ABRYSVO®, for adults aged 18 to 59 who are at increased risk for respiratory syncytial virus (RSV) disease. This approval, announced on October 22, 2024, allows eligible adults to receive the vaccine to prevent lower respiratory tract infections caused by RSV. The approval is seen as a significant step in addressing the health needs of younger adults with chronic conditions who are more vulnerable to RSV. Additionally, the FDA has granted Pfizer a broader label for its RSV vaccine compared to rival vaccines from GlaxoSmithKline (GSK) and Moderna, although the impact on market share remains uncertain.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%